Cargando…
Preclinical Assessment of wt GNE Gene Plasmid for Management of Hereditary Inclusion Body Myopathy 2 (HIBM2)
Hereditary Inclusion Body Myopathy (HIBM2) is a chronic progressive skeletal muscle wasting disorder which generally leads to complete disability before the age of 50 years. There is currently no effective therapeutic treatment for HIBM2. Development of this disease is related to expression in famil...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Libertas Academica
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2733101/ https://www.ncbi.nlm.nih.gov/pubmed/19787087 |
_version_ | 1782171090693390336 |
---|---|
author | Jay, Chris Nemunaitis, Gregory Nemunaitis, John Senzer, Neil Hinderlich, Stephan Darvish, Daniel Ogden, Julie Eager, John Tong, Alex Maples, Phillip B |
author_facet | Jay, Chris Nemunaitis, Gregory Nemunaitis, John Senzer, Neil Hinderlich, Stephan Darvish, Daniel Ogden, Julie Eager, John Tong, Alex Maples, Phillip B |
author_sort | Jay, Chris |
collection | PubMed |
description | Hereditary Inclusion Body Myopathy (HIBM2) is a chronic progressive skeletal muscle wasting disorder which generally leads to complete disability before the age of 50 years. There is currently no effective therapeutic treatment for HIBM2. Development of this disease is related to expression in family members of an autosomal recessive mutation of the GNE gene, which encodes the bifunctional enzyme UDP-GlcNAc 2-epimerase/ManNAc kinase (GNE/MNK). This is the rate limiting bifunctional enzyme that catalyzes the first 2 steps of sialic acid biosynthesis. Decreased sialic acid production, consequently leads to decreased sialyation of a variety of glycoproteins including the critical muscle protein alpha-dystroglycan (α-DG). This in turn severely cripples muscle function and leads to the onset of the syndrome. We hypothesize that replacing the mutated GNE gene with the wildtype gene may restore functional capacity of GNE/MNK and therefore production of sialic acid, allowing for improvement in muscle function and/or delay in rate of muscle deterioration. We have constructed three GNE gene/CMV promoter plasmids (encoding the wildtype, HIBM2, and Sialuria forms of GNE) and demonstrated enhanced GNE gene activity following delivery to GNE-deficient CHO-Lec3 cells. GNE/MNK enzyme function was significantly increased and subsequent induction of sialic acid production was demonstrated after transfection into Lec3 cells with the wild type or R266Q mutant GNE vector. These data form the foundation for future preclinical and clinical studies for GNE gene transfer to treat HIBM2 patients. |
format | Text |
id | pubmed-2733101 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | Libertas Academica |
record_format | MEDLINE/PubMed |
spelling | pubmed-27331012009-09-28 Preclinical Assessment of wt GNE Gene Plasmid for Management of Hereditary Inclusion Body Myopathy 2 (HIBM2) Jay, Chris Nemunaitis, Gregory Nemunaitis, John Senzer, Neil Hinderlich, Stephan Darvish, Daniel Ogden, Julie Eager, John Tong, Alex Maples, Phillip B Gene Regul Syst Bio Original Research Hereditary Inclusion Body Myopathy (HIBM2) is a chronic progressive skeletal muscle wasting disorder which generally leads to complete disability before the age of 50 years. There is currently no effective therapeutic treatment for HIBM2. Development of this disease is related to expression in family members of an autosomal recessive mutation of the GNE gene, which encodes the bifunctional enzyme UDP-GlcNAc 2-epimerase/ManNAc kinase (GNE/MNK). This is the rate limiting bifunctional enzyme that catalyzes the first 2 steps of sialic acid biosynthesis. Decreased sialic acid production, consequently leads to decreased sialyation of a variety of glycoproteins including the critical muscle protein alpha-dystroglycan (α-DG). This in turn severely cripples muscle function and leads to the onset of the syndrome. We hypothesize that replacing the mutated GNE gene with the wildtype gene may restore functional capacity of GNE/MNK and therefore production of sialic acid, allowing for improvement in muscle function and/or delay in rate of muscle deterioration. We have constructed three GNE gene/CMV promoter plasmids (encoding the wildtype, HIBM2, and Sialuria forms of GNE) and demonstrated enhanced GNE gene activity following delivery to GNE-deficient CHO-Lec3 cells. GNE/MNK enzyme function was significantly increased and subsequent induction of sialic acid production was demonstrated after transfection into Lec3 cells with the wild type or R266Q mutant GNE vector. These data form the foundation for future preclinical and clinical studies for GNE gene transfer to treat HIBM2 patients. Libertas Academica 2008-06-20 /pmc/articles/PMC2733101/ /pubmed/19787087 Text en © 2008 by the authors http://creativecommons.org/licenses/by/3.0 This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Original Research Jay, Chris Nemunaitis, Gregory Nemunaitis, John Senzer, Neil Hinderlich, Stephan Darvish, Daniel Ogden, Julie Eager, John Tong, Alex Maples, Phillip B Preclinical Assessment of wt GNE Gene Plasmid for Management of Hereditary Inclusion Body Myopathy 2 (HIBM2) |
title | Preclinical Assessment of wt GNE Gene Plasmid for Management of Hereditary Inclusion Body Myopathy 2 (HIBM2) |
title_full | Preclinical Assessment of wt GNE Gene Plasmid for Management of Hereditary Inclusion Body Myopathy 2 (HIBM2) |
title_fullStr | Preclinical Assessment of wt GNE Gene Plasmid for Management of Hereditary Inclusion Body Myopathy 2 (HIBM2) |
title_full_unstemmed | Preclinical Assessment of wt GNE Gene Plasmid for Management of Hereditary Inclusion Body Myopathy 2 (HIBM2) |
title_short | Preclinical Assessment of wt GNE Gene Plasmid for Management of Hereditary Inclusion Body Myopathy 2 (HIBM2) |
title_sort | preclinical assessment of wt gne gene plasmid for management of hereditary inclusion body myopathy 2 (hibm2) |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2733101/ https://www.ncbi.nlm.nih.gov/pubmed/19787087 |
work_keys_str_mv | AT jaychris preclinicalassessmentofwtgnegeneplasmidformanagementofhereditaryinclusionbodymyopathy2hibm2 AT nemunaitisgregory preclinicalassessmentofwtgnegeneplasmidformanagementofhereditaryinclusionbodymyopathy2hibm2 AT nemunaitisjohn preclinicalassessmentofwtgnegeneplasmidformanagementofhereditaryinclusionbodymyopathy2hibm2 AT senzerneil preclinicalassessmentofwtgnegeneplasmidformanagementofhereditaryinclusionbodymyopathy2hibm2 AT hinderlichstephan preclinicalassessmentofwtgnegeneplasmidformanagementofhereditaryinclusionbodymyopathy2hibm2 AT darvishdaniel preclinicalassessmentofwtgnegeneplasmidformanagementofhereditaryinclusionbodymyopathy2hibm2 AT ogdenjulie preclinicalassessmentofwtgnegeneplasmidformanagementofhereditaryinclusionbodymyopathy2hibm2 AT eagerjohn preclinicalassessmentofwtgnegeneplasmidformanagementofhereditaryinclusionbodymyopathy2hibm2 AT tongalex preclinicalassessmentofwtgnegeneplasmidformanagementofhereditaryinclusionbodymyopathy2hibm2 AT maplesphillipb preclinicalassessmentofwtgnegeneplasmidformanagementofhereditaryinclusionbodymyopathy2hibm2 |